Name: PRELUDE THERAPEUTICS INC (PRLD) Stock
Brand: PRELUDE THERAPEUTICS INC
Rating: 7 (3 reviews)

PRLD Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

4 days ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

14 days ago - By: Schall Law

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

17 days ago - By: Zacks Investment Research - Mentions: GS M AMGN MMM ...

Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus

4 months ago - By: The Motley Fool

Prelude Cuts Q2 Losses and Costs 13%

20 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD

21 days ago - By: Schall Law

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

21 days ago - By: FN Media Group LLC - Mentions: ONCY ALXO ERAS IMRX

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

a month ago - By: Benzinga - Mentions: ALKS ENGN IMMP MLSS ...

12 Health Care Stocks Moving In Thursday's After-Market Session

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: The Schall Law Firm

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

a month ago - By: Benzinga - Mentions: ACET RIGL TEM AKTX ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Strategic Business Update

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Strategic Business Update

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

a month ago - By: Prelude Therapeutics, Incorporated - Mentions: INCY

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

a month ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

2 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

2 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

4 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

6 months ago - By: Prelude Therapeutics, Incorporated

PRELUDE THERAPEUTICS INC (PRLD) Stock News

PRLD Latest News, Press Relases and Analysis